New York, May 30, 2026, 14:08 (EDT)
MediWound Ltd. closed Friday at $14.33, off 1.6% for the day and down about 13.6% since May 22. The market cut its outlook for the wound-care drug company’s near-term revenue. Shares slid hardest on Wednesday, dropping 14.1% on 451,100 shares traded.
MediWound shares moved lower even as the Nasdaq Composite finished higher on Friday, ending its best two-month run in over 20 years. The selloff stands out, pointing to questions around the company and not a broad biotech slump.
MediWound reported first-quarter revenue dropped to $1.5 million, down from $4.0 million in the same period last year, according to a filing. Net loss increased to $3.0 million, or 23 cents per share, compared with a $0.7 million loss, or 7 cents a share, a year ago. The company kept its 2026 revenue guidance at $24 million to $26 million, with most sales expected later in the year.
The disconnect between MediWound’s flat full-year outlook and a sluggish Q1 was the main focus for traders heading into the weekend. BARDA, the U.S. Biomedical Advanced Research and Development Authority, provides funding for public health emergencies. For MediWound, investors want to know when those government burn-care contracts translate into actual revenue.
MediWound CEO Ofer Gonen said enrollment for the late-stage VALUE trial for EscharEx has been slower than planned. But Gonen also pointed to expected revenue help in the second half from government and military NexoBrid contracts. The VALUE trial is a Phase III study, which is a large, late-stage clinical trial ahead of a possible regulatory application.
EscharEx is under trial for venous leg ulcers, which are slow to heal due to poor blood flow in veins. Debridement removes dead or damaged tissue to help wounds repair. The company is running the study with 216 patients at around 40 locations in the US, Europe and Israel. It now sees an interim review and finishing enrollment by the end of the first quarter of 2027.
Smith+Nephew’s SANTYL ointment is approved by the FDA and prescribed to clear away damaged tissue in wounds. MediWound puts its EscharEx up against SANTYL, calling it the main standard for enzymatic debridement. The matchup is narrow but matters.
Vericel’s 10-year BARDA deal for NexoBrid could reach $197 million, with a $35 million base period. Around $10 million will go to initial procurement and inventory over the next 12 months. CEO Nick Colangelo called the contract a sign of NexoBrid’s “clinical value” and said it would “support U.S. national preparedness.” Vericel Corporation
Analysts gave mixed takes on the week. Oppenheimer lowered its price target to $32 from $33 but stuck with an Outperform rating, meaning the firm still expects the stock to beat the market or sector. The broker also pointed to risk from revenue timing tied to BARDA guidance.
H.C. Wainwright’s Swayampakula Ramakanth kept a Buy on the stock with a $36 price target. Ramakanth called the VALUE trial delay an operational issue and not a problem with the design or efficacy. He also cited the BARDA contract and expected recovery in NexoBrid shipments.
But there’s a clear risk on the downside. Delays in BARDA buying, shipment pushes, manufacturing changes in Europe or the next U.S. inspection could hit MediWound’s second-half ramp. Cash dropped to $45 million from $54 million at year-end; $9.6 million went out on operating activities last quarter.
U.S. equity markets stayed closed Saturday after the week was already trimmed by Monday’s Memorial Day break. Nasdaq’s usual session is Monday to Friday, 9:30 a.m. to 4 p.m. Eastern. The next full-day closure is Juneteenth on June 19, so traders are watching if MediWound stays above its recent low and whether analyst estimates change again after the earnings call.
